On Minimizing Risk and Harm in the Use of Psychedelics.
Jules Evans, Marc Aixalà, Brian T Anderson, William Brennan, Rebecka Bremler, Joost J. Breeksema, Lisa Burback, Abigail E. Calder, Robin Carhart-Harris, Katherine Cheung, Neşe Devenot, Ingmar Gorman, Jakub Greń, Peter S. Hendricks, Brian Holoyda, Edward Jacobs, Joy Krecké, Daniel J. Kruger, David Luke, Tomislav Majić, Amy L. Mcguire, Nicky J. Mehtani, David S. Mathai, Kristin Nash, Tehseen Noorani, Roman Palitsky, Oliver Robinson, Otto Simonsson, Elin Stahre, Michiel van Elk, David B. Yaden
Psychiatric Research and Clinical Practice February 11, 2025 DOI: 10.1176/appi.prcp.20240128 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Survey Peer reviewed |
|---|---|
| Sample size | 30 |
| Population | Psychedelic researchers |
| Topics | Psychedelic-assisted therapy |
| Keywords | Mental health safety Therapeutic protocols Harm reduction Clinical guidelines |
| Citations | 18 |
| Key findings | Critical research gaps include defining types of psychedelic harm, predicting those harms, and treating them effectively, along with a call for better support and funding for a psychedelic safety net. |
Abstract
Objective: This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net.
Methods: A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and safety.
Results: The critical research gaps identified by the authors included defining the main types of psychedelic harm, the predictors of those harms, and the most effective way to treat those harms. They also call for better support for those experiencing post-psychedelic difficulties, including better online information, peer support groups, affordable therapy, and psychiatric consultation and medication. Finally, the authors call for better funding to create a psychedelic safety net, and suggest psychedelic philanthropists, investors and companies could commit 1% of their investment in psychedelics into supporting safety measures such as research and support services.
Conclusions: The authors identify several practical steps to create a better psychedelic safety net and call for more funding to psychedelic safety measures such as research and support services. Relevance to clinical practice: The authors outline important gaps in our knowledge around the safety and risk profile of psychedelic medicines and identify practical steps forward for researchers and clinical practitioners to make this promising field safer.
Comparable studies
Other cross-sectional and survey studies on psychedelic-assisted therapy, most cited first.
Citations in the library
Cited by 23
- The science of psychedelic medicine. Nature Medicine February 6, 2026
- Key competencies for psychedelic treatment in real-world mental health care settings. General Hospital Psychiatry 2025
- Anthropology of Psychedelics Anthropology of Consciousness April 20, 2025
- Classifying Psychedelic-Related Complications Current Topics in Behavioral Neurosciences 2026
- Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences. International Journal of Drug Policy December 13, 2025
and 18 more in the library
Cites 27
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Predicting Responses to Psychedelics: A Prospective Study Frontiers in Pharmacology November 2, 2018
- Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacology & Translational Science March 5, 2021
- Psychedelics alter metaphysical beliefs. Scientific Reports November 23, 2021
- Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review Journal of Psychopharmacology August 26, 2022
and 22 more in the library